Success story: PromiSeb (Sebclair)

PromiSeb (as it is known in the US) or Sebclair (brand used in Europe) is a novel steroid-free cream containing multiple active ingredients. It has been gaining popularity in treating SD as evidenced by the two stories below.

The first story comes from rosacea-support.org:

About 10 years ago my Family Doctor/Internist gave prescribed Hydro cortisone.
My face was bleeding at times.
What Crap….I fired him.
Then a dermatologist prescribed Traimcinolone acetonide cream. This worked better….
But when I washed my face in the shower with soap…….afterwards my face felt like I had a sunburn.
I has already gotten accustomed to having “dandruff” all over my shirt from my face
Recently he turned me on to Promiseb. He said……..they are using a different approach……it works for some.
See if it works for you.

Wow……..No more sunburn……No more dandruff

What really turns me on is that it is based upon a let the skin heal concept rather than the nasty steroids. Ask your Doc for some free samples.

The second story is from hairlosstalk.com:

I’m not sure how relevant this is for a hairloss forum, but after reading quite a few posts where people have SD, I figured I’d let everyone in on the good news.

It’s called PromiSeb (see what they did there?) and it cleared up my entire face in about 2 weeks!! Before that I was on Xolegel (ketoconazole), and that was OK, but I was still getting flakes and stuff so I went back to my derm and she gave me this stuff. I guess PromiSeb is pretty new, so my derm gave me a bunch of free samples, so ask for those if you go because I still haven’t looked in to how much it costs.

I honestly can’t get over how good it’s working so if you have SD, check it out

What science says

This paper investigates cream’s effectiveness in treating facial seborrheic dermatitis.

Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial, J Eur Acad Dermatol Venereol. 2008 Mar;22(3):290-6. S Veraldi, A Menter, M Innocenti, Institute of Dermatological Sciences, University of Milan, IRCCS Foundation, Policlinico, Mangiagalli and Regina Elena Hospital, Milan, Italy; Baylor University Medical Centre, Dallas, TX, USA, European Institute of Dermatology, Milan, Italy

Aim: MAS064D (Sebclair) is a novel steroid-free cream containing multiple active ingredients. Objective of this pilot study was to evaluate the efficacy and safety of MAS064D in the treatment of mild to moderate SD of the face.

Methods: Patients (n= 60) with SD were randomized to receive MAS064D (n= 40) or a matching vehicle (n = 20). The primary study endpoint was investigators’ global assessment (IGA) score at day 28, compared with baseline. Secondary endpoints included: IGA score at day 14; investigators’ assessment of erythema and scaling; patients’ assessment of burning/stinging, pruritus and global response to MAS064D; resort to rescue medication; quality of life.

Results: Use of MAS064D for 4 weeks was associated with a higher percentage of success in the MAS064D group than in the vehicle group (~68% vs 11%, P < 0.0001). The effects of MAS064D were significantly better than those of vehicle for investigator-assessed erythema and scaling, and patients’ assessed pruritus and global response to MAS064D (P ≤ 0.01). No patient in the MAS064D
group required rescue medication, compared with two patients in the vehicle group. Four patients (two each in the MAS064D and vehicle groups) reported a total of six non-serious adverse events.

Conclusions: MAS064D appears to be an effective and well tolerated cream for the treatment of mild to moderate SD of the face. Further clinical evaluation of MAS064D in SD is warranted.

The study shows that Promiseb/Sebclair has led to a significant improvement of the condition for about 2 out of every 3 patients, which is quite a good result. The authors admit that it is difficult to know which compound is responsible for Sebclair’s success as a treatment. They hypothesize that the major activity is due to the synergistic effect of both piroctone olamine, for its antimycotic action, and glycyrrhetinic acid, for its anti-inflammatory action.

The full list of ingredients is provided below: